GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » Institutional Ownership

Catalyst Pharmaceuticals (FRA:CN2) Institutional Ownership : 51.60% (As of May. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Catalyst Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Catalyst Pharmaceuticals's institutional ownership is 51.60%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Catalyst Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Catalyst Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 80.44%.


Catalyst Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Catalyst Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Institutional Ownership Chart

Catalyst Pharmaceuticals Historical Data

The historical data trend for Catalyst Pharmaceuticals can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 66.04 66.36 53.07 50.11 50.53 49.19 47.10 48.00 50.00 51.60

Catalyst Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Catalyst Pharmaceuticals (FRA:CN2) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals (FRA:CN2) Headlines

No Headlines